Onalabs Opens a Subsidiary in Andorra to Grow in Digital Health

Onalabs, the biotechnological startup specializing in the development of digital devices for complex chronic patients hospitalized at home has taken another step in its growth and internationalization with the creation of a subsidiary in Andorra la Vella, which is called Onalabs-AD Digital Health.

Through the new subsidiary, and thanks to the support of Andorra Recerca I Innovació (ARI), Onalabs will immediately start two pilot programs in the principality, focused on the field of health and sports health.

The two pilot programs will start simultaneously and will take place during the first quarter of 2023. In the first pilot, which Onalabs is promoting with the Andorrà Health Care Service (Saas), the Hospital Nostra Senyora de Meritxell, and Dr. Efrem Gómez, head of the department of angiology and vascular surgery at this health center, the Ona Vital device will perform a real-time follow-up of the postoperative period of patients with vascular pathologies.

Read more about Onalabs and find the most important financial news of the day with our companion app Born2Invest

Onalabs will immediately start two pilot programs in the principality

For the second pilot, Onalabs and the Andorran Sports Cluster have designed the pilot program aimed at the sports sector with the objective that athletes, clubs, federations, and the Ordino Sports Technification Center can use the different functionalities and applications of the Ona device Sport. The purpose is to obtain parameters that improve the performance of athletes and also prevent possible future injuries.

Ona Vital monitors vital signs such as heart rate, oxygen saturation, temperature, or physical activity of the patient in real-time. In wearable format, the device keeps its sensors in permanent contact with the person’s skin. The equipment is connected via Bluetooth to the user’s mobile phone or tablet, but also to the management systems of health centers, social health centers, and home care companies.

The company already has fifty potential clients from the medical and sports fields, which place sales in 2023 of around 10,000 devices and a turnover equivalent to €3 million.

The company estimates that it will sell around 10,000 devices in 2023

Onalabs has so far achieved investments that exceed €1.5 million. The last round, of €250,000, was closed in July of last year with the Andorra Business Market, organized by Andorra Business. In addition, the company is preparing its next entry on the BME, on a date not yet defined, but not far away.

Onalabs was created in December 2016 by Elisabet del Valle and Xavier Muñoz, the company’s CEO and scientific consultant, respectively. The company, based in the Barcelona municipality of Cerdanyola and now a subsidiary in Andorra, develops non-invasive digital devices for the fields of health and sports.

__

(Featured image by AlexFedini via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.